AstraZeneca tests new drug AZD0292 in healthy japanese adults

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy Japanese participants with suitable veins for cannulation or repeated venipuncture. * Women of childbearing potential (WOCBP) must have a negative pregnancy test and must not be lactating. * Participants must agree to use an approved method of highly effective contraception as defined in the protocol. * Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 45 kg at screening. Exclusion Criteria: * History of any clinically important disease or disorder which may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study. * History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * History of malignancy, other than treated non-melanoma skin cancers or locally-treated cervical cancer, in the previous 5 years. * Any clinically important illness, chronic infections or individuals who are at increased risk of infection. * History of acquired or inherited immunodeficiency disorders. * History of severe coronavirus disease 2019 (COVID-19) infection requiring hospitalization within the last 12 months or clinical history compatible with ongoing long COVID-19. * Current smokers or those who have smoked or used nicotine products within the previous 6 months prior to screening. * History of alcohol or drug abuse within the past 2 years. * History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD0292 and excipients contained in AZD0292. * Known hypersensitivity to antihistamines.